Inactive Instrument

Mirati Therapeutics

MRTX

US60468T1051

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) added to Russell 3000 Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Mirati Therapeutics

British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	Jan. 24	RE
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Biotechnology Select Industry Index	Jan. 24	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P TMI Index	Jan. 24	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from S&P Global BMI Index	Jan. 24	CI
Bristol-Myers Squibb Closes Acquisition of Mirati Therapeutics	Jan. 23	MT
Bristol-Myers Squibb Closes Mirati Therapeutics Acquisition	Jan. 23	MT
Bristol Myers: acquisition of Mirati Therapeutics finalized	Jan. 23	CF
Mirati Therapeutics, Inc. Announces Management Changes	Jan. 23	CI
Mirati Therapeutics, Inc.(NasdaqGM:MRTX) dropped from NASDAQ Composite Index	Jan. 23	CI
Bristol-Myers Squibb Company completed the acquisition of Mirati Therapeutics, Inc. from a group of shareholders.	Jan. 22	CI
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index	Jan. 22	CI
Mirati Therapeutics' Krazati Lung Cancer Treatment Gets EU Conditional Marketing Authorization	Jan. 10	MT
Bristol Myers expects to launch 16 new products through 2030 - CEO	Jan. 08	RE
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	MT
US FDA turns down Amgen lung cancer drug Lumakras for full approval	Dec. 26	RE
Bristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 Billion	Dec. 26	MT
Bristol-Myers Squibb Strikes $14 Billion Deal to Acquire Karuna Therapeutics	Dec. 22	MT
North American Morning Briefing : Stock Futures -2-	Dec. 21	DJ
Citigroup Downgrades Mirati Therapeutics to Neutral From Buy, Raises Price Target to $59 From $48	Dec. 20	MT
Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure	Nov. 10	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Stifel Downgrades Mirati Therapeutics to Hold From Buy, Cuts Price Target to $59 From $83	Nov. 07	MT
Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q3 Revenue $16.4M	Nov. 06	MT
Mirati Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Sector Update: Health Care Stocks Rising Late Afternoon	Nov. 02	MT

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Sector

More about the company